Published Studies Related to Refludan (Lepirudin)
Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation. [2002.10.01]
BACKGROUND: The number of indications for recombinant human hirudin lepirudin therapy has increased in recent years, and now includes acute coronary syndromes and heparin-induced thrombocytopenia. Hence, point of care monitoring appears desirable for therapy with lepirudin. As CoaguChek Plus (CCP) provides a rapid bedside test to monitor therapy with other anticoagulants, we aimed to determine its suitability for lepirudin therapy... CONCLUSION: CCP-aPTT is suitable for longitudinal point of care monitoring of lepirudin therapy. As baseline values of CCP-aPTT are shorter than STA-aPTT, it is recommended not to indiscriminately change between methods in the follow-up of individual patients.
Lepirudin blunts endotoxin-induced coagulation activation. [2000.03.01]
During sepsis, lipopolysaccharide (LPS) triggers the development of disseminated intravascular coagulation (DIC) via the tissue factor-dependent pathway of coagulation resulting in massive thrombin generation and fibrin polymerization...
Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. [1999.10]
OBJECTIVES: The purpose of this study was to compare recombinant hirudin and heparin as adjuncts to streptokinase thrombolysis in patients with acute myocardial infarction (AMI). BACKGROUND: Experimental studies and previous small clinical trials suggest that specific thrombin inhibition improves early patency rates and clinical outcome in patients treated with streptokinase... CONCLUSIONS: Lepirudin as adjunct to thrombolysis with streptokinase did not significantly improve restoration of blood flow in the infarct vessel as assessed by angiography, but was associated with an accelerated ST resolution. There was no increase in the risk of major bleedings with lepirudin compared to heparin.
Lepirudin as an alternative to "heparin allergy" during cardiopulmonary bypass. [2011.04.08]
A treatment strategy of a difficult and unusual problem is presented. We are reporting a case of a patient who had a documented allergy to heparin and required Cardiac surgery for an ASD closure... Therefore this case is unique not only because of its rarity but also by the fact that it presents the caveats encountered when ECT is not available.
Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease. [2010.02]
The direct thrombin inhibitor lepirudin is mainly applied in heparin-induced thrombocytopenia. We report here the case of a 37-year-old kurdish woman in whom Behcets disease was diagnosed in 1998 when she presented with a Budd Chiari syndrome (BCS) complicated by pulmonary embolism... If stepwise dose lowering is required over time, the presence of lepirudin antibodies should be considered.
Clinical Trials Related to Refludan (Lepirudin)
Argatroban Versus Lepirudin in Critically Ill Patients [Terminated]
Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices [Completed]
This study will compare the effectiveness of two blood thinners, heparin and lepirudin, in
preventing withdrawal occlusion (blockage) in a venous access device (VAD). A VAD is a
catheter (plastic tube) placed in a vein beneath the collarbone to deliver medication and
withdraw blood samples during treatment. The device may become clogged, possibly by
formation of a clot around the tip, blocking its opening and making it difficult or
impossible to use. The clot can be dissolved by a medication called tPA. The blood thinner
heparin has been used for many years to try to prevent the blockage from occurring, but it
is still a problem in as many as 25 percent of VADs. This study will test whether a new
blood thinner called lepirudin is more effective than heparin in preventing withdrawal
occlusion caused by a small clot.
Patients 21 years of age and older who are enrolled in NIH protocols at the Clinical Center
and who require tunneled, open-ended VADs for their medical care may be eligible for this
study. Candidates must expect to receive all of their primary medical care at the Clinical
Center during the first 4 weeks after their VAD is inserted and most of their care at the
Clinical Center for the next 3 months.
Participants will be randomly assigned to receive either heparin or lepirudin flushes for
the first 3 or 4 weeks after placement of their VAD-the period during which withdrawal
occlusion is most likely to occur. After this period, all patients will use routine heparin
flushes until the VAD is removed.
The patient's VAD will be closely monitored for withdrawal occlusion during the 3- to 4-week
test period and will continue to be observed for up to 3 months to check for lasting effects
of the blood thinner.
Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer [Completed]
RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in
patients who have received chemotherapy for small cell lung cancer.
PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in
treating patients with recurrent or advanced small cell lung cancer.
Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II [Completed]
The purpose of this retrospective registry is to collect data about patients with acute HIT
II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid,
Argatroban or Fondaparinux. It is a main objective of this registry to mirror the daily
routine in this indication in Germany.
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) [Withdrawn]
The purpose of this study is to test the safety and efficacy of fondaparinux in patients
with heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that
patients with HIT who are treated with fondaparinux experience a prompt and complete
recovery of their platelet count, and the secondary objective is to determine if any new
blood clots are formed while receiving the fondaparinux and up to one month after study
enrollment. This information will be compared to a historical control.
Reports of Suspected Refludan (Lepirudin) Side Effects
Injection Site Extravasation (2),
Respiratory Disorder (1),
Myocardial Ischaemia (1),
Wound Haemorrhage (1),
Activated Partial Thromboplastin Time Prolonged (1), more >>